Department of Sciences and Technologies, University of Sannio, 82100 Benevento, Italy.
Medical Oncology Unit, Fatebenefratelli Hospital, 82100 Benevento, Italy.
J Immunol Res. 2014;2014:686879. doi: 10.1155/2014/686879. Epub 2014 Jan 16.
Over the past decade, growing evidence indicates that the tumor microenvironment (TME) contributes with genomic/epigenomic aberrations of malignant cells to enhance cancer cells survival, invasion, and dissemination. Many factors, produced or de novo synthesized by immune, stromal, or malignant cells, acting in a paracrine and autocrine fashion, remodel TME and the adaptive immune response culminating in metastasis. Taking into account the recent accomplishments in the field of immune oncology and using metastatic colorectal cancer (mCRC) as a model, we propose that the evasion of the immune surveillance and metastatic spread can be achieved through a number of mechanisms that include (a) intrinsic plasticity and adaptability of immune and malignant cells to paracrine and autocrine stimuli or genotoxic stresses; (b) alteration of positional schemes of myeloid-lineage cells, produced by factors controlling the balance between tumour-suppressing and tumour-promoting activities; (c) acquisition by cancer cells of aberrant immune-phenotypic traits (NT5E/CD73, CD68, and CD163) that enhance the interactions among TME components through the production of immune-suppressive mediators. These properties may represent the driving force of metastatic progression and thus clinically exploitable for cancer prevention and therapy. In this review we summarize results and suggest new hypotheses that favour the growing impact of tumor-infiltrating immune cells on tumour progression, metastasis, and therapy resistance.
在过去的十年中,越来越多的证据表明肿瘤微环境(TME)通过恶性细胞的基因组/表观基因组异常促进癌细胞的存活、侵袭和扩散。许多因素,由免疫、基质或恶性细胞产生或从头合成,以旁分泌和自分泌的方式重塑 TME 和适应性免疫反应,最终导致转移。考虑到免疫肿瘤学领域的最新成就,并以转移性结直肠癌(mCRC)为例,我们提出,免疫监视的逃避和转移的发生可以通过多种机制来实现,包括:(a)免疫和恶性细胞对旁分泌和自分泌刺激或遗传毒性应激的内在可塑性和适应性;(b)由控制肿瘤抑制和肿瘤促进活性之间平衡的因素产生的髓系细胞位置方案的改变;(c)癌细胞获得异常的免疫表型特征(NT5E/CD73、CD68 和 CD163),通过产生免疫抑制介质增强 TME 成分之间的相互作用。这些特性可能代表转移进展的驱动力,因此可用于癌症的预防和治疗。在这篇综述中,我们总结了结果,并提出了新的假说,支持浸润肿瘤的免疫细胞对肿瘤进展、转移和治疗耐药性的日益增长的影响。